Suppr超能文献

2型糖尿病和糖尿病肾病患者中转化生长因子β1的变化:一项遵循PRISMA标准的系统评价和荟萃分析。

Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis.

作者信息

Qiao Yong-Chao, Chen Yin-Ling, Pan Yan-Hong, Ling Wei, Tian Fang, Zhang Xiao-Xi, Zhao Hai-Lu

机构信息

Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin Department of Immunology, Xiangya School of Medicine, Central South University, Changsha, Hunan Department of Immunology, Faculty of Basic Medicine, Guilin Medical University, Guilin, China.

出版信息

Medicine (Baltimore). 2017 Apr;96(15):e6583. doi: 10.1097/MD.0000000000006583.

Abstract

BACKGROUND

The existing evidence indicates increased levels of transforming growth factor beta 1 (TGF-β1) in patients with type 2 diabetes mellitus (T2DM) and those with type 2 diabetic nephropathy (T2DN); yet no meta-analysis displays a reliable result. Here we conducted a meta-analysis to evaluate characteristic changes of TGF-β1 in T2DM and diabetic nephropathy.

METHODS

A systematic search was conducted for eligible studies, which reported the association of TGF-β1 withT2DM and T2DN patients, in PubMed, Wangfang, Chinese-Cqvip, and China National Knowledge Infrastructure database, from February 1, 1991 to December 15, 2015. The association of serum and urine TGF-β1 in T2DM and T2DN patients should be evaluated in case-control studies. The Newcastle-Ottawa Scale was used to access the quality of the included studies, and pooling data were synthesized as standard mean difference (SMD) and 95% confidence interval (CI). The collected data were synthesized according to Cochrane Handbook for Systematic Reviews criteria. Subgroup analysis was conducted by albuminuria and ethnicity. Regression analysis and sensitivity analysis were used to explore the sources of heterogeneity. Publication bias was judged by the Egger test.

RESULTS

Sixty-three case-control studies of 364 T2DM patients (1604 T2DN patients) and 2100 healthy controls were included for meta-analysis. Compared with the controls, the cases had increased TGF-β1 levels in both serum (T2DM: SMD 1.78 μg/L; 95% CI 0.98-2.59, P < .001; T2DN: SMD 4.70 μg/L, 95% CI 3.55-5.85, P < .001) and urine samples (T2DM: SMD 1.27 pg/mg.creatinine, 95% CI 0.16-2.38, P < .001; SMD 1.19 ng/L, 95% CI 0.77-1.62, P < .001; T2DN: SMD 3.14 pg/mg.creatinine, 95% CI 2.15-4.13, P < .001; SMD 4.50 ng/L, 95% CI 3.16-5.83, P < .001). The increase of serum TGF-β1 persisted in patients with either microalbuminuria or macroalbuminuria (all P < .001) in Chinese and non-Chinese population. High heterogeneity exists in some comparisons and small-sample studies.

CONCLUSIONS

Patients with T2DM and those with albuminuria, Chinese or non-Chinese, had increased serum and urine TGF-β1 levels.

摘要

背景

现有证据表明,2型糖尿病(T2DM)患者和2型糖尿病肾病(T2DN)患者体内的转化生长因子β1(TGF-β1)水平升高;然而,尚无荟萃分析得出可靠结果。在此,我们进行了一项荟萃分析,以评估T2DM和糖尿病肾病中TGF-β1的特征性变化。

方法

于1991年2月1日至2015年12月15日在PubMed、万方、中国知网和中国生物医学文献数据库中系统检索符合条件的研究,这些研究报告了TGF-β1与T2DM和T2DN患者的相关性。病例对照研究应评估T2DM和T2DN患者血清和尿液中TGF-β1的相关性。采用纽卡斯尔-渥太华量表评估纳入研究的质量,并将汇总数据合成为标准均数差(SMD)和95%置信区间(CI)。收集的数据根据Cochrane系统评价手册标准进行合成。按蛋白尿和种族进行亚组分析。采用回归分析和敏感性分析探讨异质性来源。通过Egger检验判断发表偏倚。

结果

纳入63项病例对照研究,共364例T2DM患者(1604例T2DN患者)和2100例健康对照进行荟萃分析。与对照组相比,病例组血清(T2DM:SMD 1.78μg/L;95%CI 0.98 - 2.59,P<0.001;T2DN:SMD 4.70μg/L,95%CI 3.55 - 5.85,P<0.001)和尿液样本(T2DM:SMD 1.27pg/mg·肌酐,95%CI 0.16 - 2.38,P<0.001;SMD 1.19ng/L,95%CI 0.77 - 1.62,P<0.001;T2DN:SMD 3.14pg/mg·肌酐,95%CI 2.15 - 4.13,P<0.001;SMD 4.50ng/L, 95%CI 3.16 - 5.83,P<0.001)中的TGF-β1水平均升高。在中国和非中国人群中,微量白蛋白尿或大量白蛋白尿患者的血清TGF-β1均持续升高(均P<0.001)。在一些比较和小样本研究中存在高度异质性。

结论

T2DM患者以及有蛋白尿的患者,无论中国人还是非中国人,血清和尿液中TGF-β1水平均升高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/621e/5403085/8b9dca0895ef/medi-96-e6583-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验